KRABEVA 100 MG INJ. VIAL.

About

KRABEVA 100 MG INJ. VIAL. is a biological therapy containing bevacizumab, a recombinant humanized monoclonal antibody that specifically targets and binds to vascular endothelial growth factor (VEGF). VEGF is a critical signaling protein that promotes angiogenesis, the formation of new blood vessels, which is essential for tumor growth, survival, and metastasis. By neutralizing VEGF, bevacizumab effectively inhibits the development of new blood vessels that supply tumors, thereby impeding their proliferation and spread. This anti-angiogenic mechanism makes Krabeva a vital component in the treatment of various advanced cancers, frequently administered in conjunction with chemotherapy regimens to enhance therapeutic efficacy and improve patient outcomes. Its targeted action helps to control disease progression and extend survival.

Uses

• Treatment of metastatic colorectal cancer.
• Management of non-small cell lung cancer.
• Therapy for metastatic renal cell carcinoma.
• Treatment of recurrent glioblastoma.

Directions For Use

Administer intravenously under the supervision of an experienced oncologist. Dosage and infusion schedule are determined by the specific cancer type and patient's body weight.

Benefits

• Inhibits tumor angiogenesis.
• Slows tumor growth and progression.
• Extends progression-free survival.
• Often used in combination with chemotherapy.
• Effective against various solid tumors.
• Improves overall survival in some indications.

Side Effects

• Hypertension (high blood pressure)
• Proteinuria (protein in urine)
• Bleeding events (epistaxis, gastrointestinal hemorrhage)
• Thromboembolic events (blood clots)
• Gastrointestinal perforation
• Fatigue
• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Wound healing complications
• Infusion-related reactions

Safety Measures

• Alcohol - No specific interaction, but alcohol should be avoided due to general health considerations during cancer treatment.
• Pregnancy - Contraindicated during pregnancy due to potential fetal harm; effective contraception is required.
• Breastfeeding - Contraindicated during breastfeeding; discontinue breastfeeding due to potential harm to the infant.
• Liver - Use with caution in patients with severe liver impairment; monitor liver function.
• Kidney - Monitor for proteinuria and renal function; dose adjustment may be needed in severe renal impairment.
• Lung - Monitor for pulmonary hemorrhage or other lung complications, especially in patients with lung cancer.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.